



**HAL**  
open science

## **CMTX1 patients' cells present genomic instability corrected by CamKII inhibitors**

Saleh Mones, Burkhardt Gess, Benoit Bordignon, Alexandre Altie, Peter Young, Frédéric Bihel, Marc Fraterno, Franck Peiretti, Michel Fontés

► **To cite this version:**

Saleh Mones, Burkhardt Gess, Benoit Bordignon, Alexandre Altie, Peter Young, et al.. CMTX1 patients' cells present genomic instability corrected by CamKII inhibitors. Orphanet Journal of Rare Diseases, 2015, 10, 10.1186/s13023-015-0270-5 . hal-02634560

**HAL Id: hal-02634560**

**<https://hal.inrae.fr/hal-02634560>**

Submitted on 27 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



# CMTX1 patients' cells present genomic instability corrected by CamKII inhibitors

Mones Saleh<sup>1†</sup>, Gess Burkhardt<sup>2,3†</sup>, Bordignon Benoit<sup>1</sup>, Altie Alexandre<sup>4</sup>, Young Peter<sup>2</sup>, Bihel Frederic<sup>5</sup>, Fraterno Marc<sup>2</sup>, Peiretti Franck<sup>1</sup> and Fontes Michel<sup>1\*</sup>

## Abstract

**Background:** We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients.

**Methods:** We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instability, connexon activity, and potential correction by CamKII inhibitors.

**Results:** The phenotypic analysis of these cells confirmed strong similarities between the *GJB1* transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors.

**Conclusions:** Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.

**Keywords:** CMT disorder, Peripheral neuropathies, Drug development

## Background

We recently created and analyzed transgenic mouse lines that expressed a human mutated *GJB1* [1] (i.e., the gene involved in the X-linked form of Charcot-Marie-Tooth disease [2]), coding for connexin 32 (Cx32), a component of gap junctions [3,4]. We demonstrated that Cx32 is involved in mitotic stability, as transgenic cells present mitotic instability (i.e., aneuploidy, or centrosome overduplication). Both our study and the European Mitocheck project ([www.mitocheck.org](http://www.mitocheck.org)) observed that a lower Cx32 expression or expression of a mutated isoform resulted in perturbation of cell division [1,5].

Moreover, in a recent article [6], we suggested that this instability is due to CamKII overexpression, thereby leading to centrosome overduplication. In 1997, Torok et al. [7] identified two calmodulin-binding domains in Cx32 and provided evidence that calmodulin may function as

an intracellular ligand, regulating Ca<sup>2+</sup>-dependent inter-cellular communication across gap junctions. Finally Dodd et al. [8] demonstrated that the physical proximity between Cx32 and Calmodulin Kinase II (CamKII) had a physiological role. It was thus likely that pathological mutations in Cx32, associated to CMTX1, resulted in mitotic instability through CamKII overexpression that led to centrosome overduplication. Furthermore, we demonstrated that treatment with CamKII inhibitors [6] (KN62 or KN93 [9]) resulted in a partial but significant rescue of abnormal centrosome overduplication, mitotic instability, and connexon activity. In addition, in vivo treatment of CMTX1-related transgenic mice with KN93 improved their locomotor performance on the rotarod.

However, these data were either obtained from transgenic mouse lines (i.e., our findings) or human transfected cells (i.e., the Mitocheck project). We could thus not presume that these findings could be translated to CMTX1 patients. We thus collected and analyzed fibroblasts from the skin biopsies of five CMTX1 patients

\* Correspondence: [michel.fontes@univ-amu.fr](mailto:michel.fontes@univ-amu.fr)

†Equal contributors

<sup>1</sup>NORT, UMR INSERM 1062, INRA 1260, Aix Marseille Université, Campus Santé La Timone, 27 boulevard Jean Moulin, Marseille 13385 Cedex 53, France  
Full list of author information is available at the end of the article

**Table 1 Results of nerve conduction studies**

	mNCV	CMAP
Patient 1	39 m/s	3.4 mV
Patient 2	45 m/s	4.0 mV
Patient 3	32 m/s	1.5 mV
Patient 4	32.4 m/s	5.1 mV
Patient 5	34.1 m/s	1.4 mV

Electrophysiological evaluations were performed on 5 patients with CMTX1, with clinical presentations described in materials and methods. Results of nerve conduction studies in terms of median nerve motor conduction velocity (NCV) and compound muscle action potential amplitudes (CMAP) are presented in the table.

that presented three different mutations. Phenotypic analysis of the patient's cells were compared to phenotypic presentation of the cells from CMTX animal models. Phenotypic correction using CamKII inhibitors was also tested.

## Methods

### Patients

Patients were evaluated at the University Hospital of Muenster. The inclusion criteria for this study required a clinical phenotype consistent with CMT and a genetic diagnosis of CMTX1. Nerve conduction studies (NCS) were performed according to standard procedures.

### Standard protocol approvals, registrations, and patient consents

All biological materials family history as well as medical and neurophysiological reports were obtained under appropriate informed consent of the patients or their legal guardians. The local ethics committees of the University of Muenster approved the study.

### Mutations and clinical presentation of patients

**Patient 1** is a female with the mutation R215W on the gene *Gjb1*. Clinically, she has distal pareses of arms and legs, gait ataxia and distal sensory loss. Age of onset: 22 years. Nerve conduction studies showed an intermediate neuropathy.


**Patient 2** is the sister of patient 1, with the same mutation R215W. Clinically, she shows pareses of foot dorsal extension, finger abduction and extension on both sides, distal symmetric sensory loss and absent achilles tendon reflexes. Age of onset: 25 years.

**Patient 3** is a male with a mutation R142W. He presents muscle atrophies and pareses of hands and calves, foot drop, distal symmetrical hyp- and dysesthesia of legs. Tendon reflexes are reduced in the arms, absent in legs. Age of onset: ca. 15 years. Nerve conduction studies showed an intermediate neuropathy.


**Patient 4** is a female with the mutation V181M. She presents pareses of foot dorsiflexion and small hand muscles, neuropathic pain in feet and hands, distal symmetric hyp- and dysesthesia of feet and fingertips. Tendon reflexes reduced in the arms, absent in legs. Age of onset: ca. 25 years. Nerve conduction studies showed an intermediate neuropathy.

**Patient 5** is a male, the son of patient 4 with the same mutation V181M. He presents pareses of foot dorsiflexion, plantar flexion, mild pareses of finger abduction and hypesthesia of feet. He shows high arched feet and hammer toes. Tendon reflexes are absent in arms and legs. Age of onset: 16 years.

Results of nerve conduction studies are presented in Table 1.



**Figure 1** Patients fibroblasts have been cultured as described in methods. Nuclei have been stained with DAPI and captured using light microscope. Examples of abnormal nuclei observed in cells of CMTX1 patients. Normal nuclei (**A, B**), Abnormal shape (**C and D**), Polylobbed (**E and F**), Non disjunction (**G and H**).



### Human fibroblast cell culture

Fibroblast cell cultures were performed as described [10]. A 1 mm skin punch biopsy was transferred to DMEM supplemented with 20% fetal calf serum, penicillin/streptomycin and glutamine (D20 medium). The tissue was transferred to a 60 mm plastic Pasteur dish and submerged in D20 medium at standard conditions. After a lawn of fibroblasts had grown, biopsy tissues

were removed and the cultures were grown and passaged 3 times before assays were performed.

### Western blotting

Cells were lysed in RIPA buffer (50 mM Tris-Cl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 0.1% SDS, 150 mM sodium chloride) supplemented with protease and phosphatase inhibitors. The same amounts of protein from each sample were resolved under denaturing and reducing conditions on 4-12% NuPAGE gels (Invitrogen) and transferred to polyvinylidene fluoride membranes. Immunoreactive proteins were revealed by enhanced chemiluminescence with ECL (Perkin-Elmer). An antibody against phosphorylated CamKII (Cell Signaling, catalog number: 3361) was used.

### Centrosome labelling

Cells were grown on glass coverslips for 24 h to allow cultures to reach 80% confluence. To measure the number of centrosomes, cells were fixed with 4% PFA, permeabilized with methanol at  $-20^{\circ}\text{C}$  for 8 min and blocked with 0.5% Triton X-100 in PBS for 30 min at RT. To detect  $\gamma$ -tubulin, cells were incubated overnight at  $4^{\circ}\text{C}$  with a mouse anti- $\gamma$ -tubulin antibody (GTU-88; Sigma) diluted 1/1000 in PBS containing 0.1% milk and 0.05% Triton X-100. After washing, the cells were incubated for 1 h at RT with Cy3-conjugated goat anti-mouse IgG secondary antibody (Caltag Laboratories) diluted 1/2000 in PBS containing 0.1% milk and 0.05% Triton X-100. The preparations were counterstained with DAPI in Vectashield mounting medium (Vector Laboratories). Fluorescent images were acquired with a microscope (Leica DMR) equipped with a PL APO objective.

### Connexon activity

One hundred thousand cells were cultured as described above for one day with or without CamKII inhibitors (KN62 or KN93 at a final concentration of  $10\ \mu\text{M}$ ). Lucifer yellow (LY) was added to the medium (final concentration:  $110\ \mu\text{M}$ ) and incubated for two hours. Fluorescence was recorded using a Perkin Elmer Victor 4 microplate reader (excitation: 405 nM, emission: 535 nM).

### Statistics

Statistical analysis was performed using Prism v5.0. Mann-Whitney and chi-square tests were used for trend analysis. The significance threshold was set at  $p < 0.05$ .

## Results and discussion

### Nuclear anomalies

As Schwann cell cultures could not be obtained from patients for practical and ethical reasons, we isolated fibroblasts from skin biopsies. Various parameters were

analyzed. Patient fibroblasts did not show significant levels of polyploidy (not shown). However, we observed an abnormal number of nuclei presenting anomalies (Figure 1). Nuclear anomalies have been described and classified by the Mitocheck project: abnormal shape (C,D), polylobbed (E,F), two unseparated nuclei (G,F) and others [5]. We next quantified the percentage of these abnormal nuclei in CMTX1 patient fibroblasts, and compared the results to human fibroblasts from individuals that did not present CMTX1. We observed only a few abnormal nuclei in reference individuals (i.e., less than 3%), whereas approximately 15% of nuclei from CMTX1 patients had anomalies (Figure 2A). We have previously showed that CamKII activity was increased in transgenic cells and that inhibitors were able to reduced anomalies in *GJB1* transgenic cell lines. We thus evaluated CamKII activity in patient fibroblasts, using an antibody raised against phosphorylated CamKII, in patients fibroblasts. We could observed, in Figure 3C, that CamKII activity is overstimulated in patient fibroblasts (Figure 3C). According to these observations, fibroblasts from CMTX1 patients were treated in vitro with the CamKII inhibitor KN93 at a concentration of 10  $\mu$ M. We found that KN93 was able to significantly reduce the amount of abnormal nuclei in fibroblasts from each CMTX1 patient, which supports our previous work on transgenic mice, (Figure 2A).

### Centrosome overduplication


Cells from five transgenic lines created in the laboratory present centrosome overuplications that are linked to mutations in *GJB1* [6]. We thus evaluated centrosome duplication in normal and CMTX1 fibroblasts, treated or untreated with the CamKII inhibitor KN93. We observed centrosome overduplication in the fibroblasts from CMTX1 patients, which supports the findings of the study on *GJB1* transgenic mice (Figures 3A, B, and 2A). As expected, this overduplication was significantly corrected by KN93 treatment (10  $\mu$ M ; Figure 2B).

### Connexon activity


Impairment of connexon activity is considered the primary cause of the CMTX1 phenotype in humans [11]. We thus evaluated the connexon activity of the fibroblasts from CMTX1 patients, using an assay developed in our laboratory [6] which is based on the measurement of Lucifer Yellow internalization that requires connexon activity. Connexon activity was found to be lower in CMTX1 patient fibroblasts as compared to healthy controls (Figure 4). After treatment with KN93, the connexon activity significantly improved in the fibroblasts of each CMTX1 patient (Figure 4).

### Conclusions

In conclusion, the fibroblasts from five CMTX1 patients showed the same cellular phenotype that we described



**Figure 3** Patients fibroblasts have been cultured and centrosomes stained as described in Methods. Pictured have been captured using a fluorescence microscope. Examples are presented in Figure 3A and B. Same cells have been lysed, and analyzed using polyacrylamide gels. Western blots have been performed and probed using an antibody raised against the phosphorylated form of CamKII (2C). 1, normal cells ; 2, cells from patient 1 ; 3, cells from patient 3 ; cells from patient 5.



**Figure 4** Connexon activity of patients cells (patient 1 to 5, **A, B, C, D** and **E**), and control human fibroblasts, has been evaluated using internalisation of Lucifer Yellow (LY). Fluorescence of LY has been recorded corresponding to cells treated or not with KN93.



in *GJB1* transgenic mouse models created in the laboratory [1,6], including nuclei anomalies, centrosome overduplication, and impaired connexon activity. As suggested by Matsumoto and Maller [12], centrosome duplication is linked to CamKII activity. In CMTX1 mice, we have already shown that CamKII inhibitors can revert the phenotype linked to mutations in the *GJB1* gene. These results suggest that the phenotype observed in the fibroblasts from CMTX1 patients can also be corrected, at least partially, by treatment with a CamKII inhibitor.

Waggner et al. recently demonstrated that CamKII is involved in myelination mechanisms in the central nervous system (CNS) [13]. They demonstrated that perturbation of CamKII beta is associated with anomalies in CNS glial cell maturation, is involved in anomalies of actin skeleton, and is associated with myelin anomalies. Recently, we demonstrated that the locomotor behaviour of *GJB1* mutated mouse models of CMTX1 can be improved by treatment with CamKII inhibitors [6]. In conclusion, the fibroblasts of human CMTX1 patients present the same phenotype as the fibroblasts of mouse models. Moreover, the same molecule (KN93) partially corrects the cellular phenotype of human and mouse fibroblasts as well as locomotor behaviour in mouse models. These findings provide a translational link from the murine to the human system. Although it is still too early to directly apply our results to human patients, for the first time, our results show a potential avenue for therapeutic approaches to CMTX1 treatment.

#### Competing interest

The authors declare that they have no competing interests.

#### Authors' contributions

AA and FM were involved in image acquisition, treatment and analysis. MS and BB, developed 96 wells analysis of connexon activity. They also performed experiments and participated in the analysis. GB examined patients, took skin biopsies and cultured fibroblasts from patients' biopsies. YP recruited patients and supervised their examination. BF was involved in CamKII inhibitor testing. PF was involved in data analysis as well as deep critical revision of the manuscript. FM was the conceptual of the study and supervised the research. All authors read and approved the final manuscript.

#### Acknowledgements

This study has been funded on by an annual recurrent budget of our unit (NORT). No extra fundings or private grants have been involved in this study.

#### Author details

<sup>1</sup>NORT. UMR INSERM 1062, INRA 1260, Aix Marseille Université, Campus Santé La Timone, 27 boulevard Jean Moulin, Marseille 13385 Cedex 53, France.

<sup>2</sup>Department of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Muenster, Germany. <sup>3</sup>Department of Neurology, Aachen RWTH University Clinic, Aachen, Germany. <sup>4</sup>Service de Microscopie Electronique, Faculté de Médecine de la Timone, 27 boulevard Jean Moulin, Marseille 13385 Cedex 53, France. <sup>5</sup>Laboratoire d'Innovation thérapeutique, UMR7200, CNRS, Université de Strasbourg, Faculté de Pharmacie, 74, route du rhin, Illkirch Graffenstaden 67400, France.

Received: 25 February 2015 Accepted: 16 April 2015

Published online: 07 May 2015

#### References

- Mones S, Bordignon B, Fontés M. Connexin 32 is involved in mitosis. *Glia*. 2012;60(3):457–64.
- Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ. Connexin mutations in X-linked Charcot-Marie-Tooth disease. *Science*. 1993;262:2039–42.
- Ahmad S, Martin PE, Evans WH. Assembly of gap junction channels: mechanism, effects of calmodulin antagonists and identification of connexin oligomerization determinants. *Eur J Biochem*. 2001;268(16):4544–52.
- Scherer SS, Deschênes SM, Xu YT, Grinspan JB, Fischbeck KH, Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. *J Neurosci*. 1995;15(12):8281–194.
- Neumann B, Walter T, Hériché JK, Bulkescher J, Erfle H, Conrad C, et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. *Nature*. 2010;464(7289):721–7.
- Mones S, Bordignon B, Peiretti F, Landrier JF, Gess B, Bourguignon JJ, et al. CamKII inhibitors reduce mitotic instability, connexon anomalies and progression of the in vivo behavioral phenotype in transgenic animals expressing a mutated *GJB1* gene. *Front Neurosci*. 2014;8:151.
- Torok K, Stauffer K, Evans WH. Connexin 32 of gap junctions contains two cytoplasmic calmodulin-binding domains. *Biochem J*. 1997;326:479–83.
- Dodd R, Peracchia C, Stolady D, Török K. Calmodulin association with connexin32-derived peptides suggests trans-domain interaction in chemical gating of gap junction channels. *J Biol Chem*. 2008;283(40):26911–20.
- Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M. The newly synthesized selective Ca<sup>2+</sup>/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. *Biochem Biophys Res Commun*. 1991;181(3):968–75.
- Gess B, Auer-Grumbach M, Schirmacher A, Strom T, Zitzelsberger M, Rudnik-Schöneborn S, et al. H5J1-related hereditary neuropathies: novel mutations and extended clinical spectrum. *Neurology*. 2014;83(19):1726–32.
- Oh S, Ri Y, Bennett M, Trexler EB, Verselis VK, Bargiello TA. Changes in permeability caused by connexin 32 mutations underlie X-linked Charcot-Marie-Tooth disease. *Neuron*. 1997;19(4):927–38.
- Matsumoto Y, Maller JL. Calcium, calmodulin, and CaMKII requirement for initiation of centrosome duplication in *Xenopus* egg extracts. *Science*. 2002;295:499–502.
- Waggner CT, Dupree JL, Elgersma Y, Fuss B. CaMKIIβ regulates oligodendrocyte maturation and CNS myelination. *J Neurosci*. 2013;33(25):10453–8.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

